These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 32667213)

  • 21. A Genetic Variant in the BCL2 Gene Associates with Adalimumab Response in Hidradenitis Suppurativa Clinical Trials and Regulates Expression of BCL2.
    Liu M; Degner J; Georgantas RW; Nader A; Mostafa NM; Teixeira HD; Williams DA; Kirsner RS; Nichols AJ; Davis JW; Waring JF
    J Invest Dermatol; 2020 Mar; 140(3):574-582.e2. PubMed ID: 31465739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hidradenitis suppurativa in the pediatric population.
    Liy-Wong C; Pope E; Lara-Corrales I
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S36-41. PubMed ID: 26470613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of patients with hidradenitis suppurativa.
    Martorell A; Caballero A; González Lama Y; Jiménez-Gallo D; Lázaro Serrano M; Miranda J; Pascual JC; Salgado-Boquete L; Marín-Jiménez I
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():32-42. PubMed ID: 28081768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
    Bechara FG; Podda M; Prens EP; Horváth B; Giamarellos-Bourboulis EJ; Alavi A; Szepietowski JC; Kirby J; Geng Z; Jean C; Jemec GBE; Zouboulis CC
    JAMA Surg; 2021 Nov; 156(11):1001-1009. PubMed ID: 34406349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents.
    Megna M; Bettoli V; Chimenti S; Chiricozzi A; Naldi L; Virgili A; Girolomoni G; Monfrecola G
    G Ital Dermatol Venereol; 2015 Dec; 150(6):731-9. PubMed ID: 26513043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.
    Zouboulis CC; Bechara FG; Dickinson-Blok JL; Gulliver W; Horváth B; Hughes R; Kimball AB; Kirby B; Martorell A; Podda M; Prens EP; Ring HC; Tzellos T; van der Zee HH; van Straalen KR; Vossen ARJV; Jemec GBE
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):19-31. PubMed ID: 30176066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective.
    Bi Y; Liu J; Wang J; Epps RE; Kettl D; Marcus K; Seo S; Zhu H; Wang Y
    AAPS J; 2019 Jul; 21(5):91. PubMed ID: 31325056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
    Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
    J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy.
    Samycia M; Brassard A
    J Cutan Med Surg; 2013 Oct; 17 Suppl 1():S23-32. PubMed ID: 24144253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
    Esme P; Akoglu G; Dalkıran CD; Caliskan E
    Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa.
    Zouboulis CC
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1015-26. PubMed ID: 27531618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unconventional therapies for hidradenitis suppurativa.
    Marasca C; Annunziata MC; Napolitano M; Fabbrocini G
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):879-887. PubMed ID: 30136871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hidradenitis suppurativa: Current and emerging treatments.
    Goldburg SR; Strober BE; Payette MJ
    J Am Acad Dermatol; 2020 May; 82(5):1061-1082. PubMed ID: 31604100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pain management in patients with hidradenitis suppurativa.
    Horváth B; Janse IC; Sibbald GR
    J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S47-51. PubMed ID: 26470616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New and Emerging Targeted Therapies for Hidradenitis Suppurativa.
    Markota Čagalj A; Marinović B; Bukvić Mokos Z
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
    Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
    Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological development in hidradenitis suppurativa.
    Matusiak Ł; Jemec GB; Szepietowski JC
    Curr Opin Pharmacol; 2019 Jun; 46():65-72. PubMed ID: 31075754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.
    Shanmugam VK; Mulani S; McNish S; Harris S; Buescher T; Amdur R
    Int J Dermatol; 2018 Jan; 57(1):62-69. PubMed ID: 29130482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hidradenitis suppurativa in a patient with Warkany syndrome: Sustainability of adalimumab treatment.
    Atzori L; Bonato F; Pilloni L; Rongioletti F
    Dermatol Ther; 2020 Jan; 33(1):e13160. PubMed ID: 31705612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.
    Stergianou D; Kanni T; Damoulari C; Giamarellos-Bourboulis EJ
    Expert Opin Biol Ther; 2024 Apr; 24(4):225-232. PubMed ID: 38602836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.